In his weekly clinical update Dr. Griffin discusses modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China, canine real-time detection of SARS-CoV-2 infections in the context of a mass screening event, two masks can be worse than one: N95 respirator failure caused by an overlying face mask, airflow patterns in double-occupancy patient rooms may contribute to roommate-to-roommate transmission of severe SARS-CoV-2, clinical validation of a novel T-Cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection, antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant, VV116 versus Nirmatrelvir–Ritonavir for oral treatment of Covid-19, Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support, FDA approves Roche’s Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults, structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction, persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium, epidemiology of long COVID in US adults, persistent symptoms and sequelae after SARS-CoV-2 infection not requiring hospitalization, and outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Modeling the adjustment of COVID-19 response and exit in China (Nature)
• Canine real-time detection of SARS-CoV-2 infections in mass screening events (BMJ)
• N95 respirator failure caused by an overlying face mask (ICHE)
• Airflow in patient rooms may contribute to transmission of severe SARS-CoV-2 (CID)
• Clinical validation of a T-Cell receptor for identification of recent or prior SARS-CoV-2 infection (CID)
• Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages (Cell)
• VV116 vs. Nirmatrelvir–Ritonavir for oral treatment of Covid-19 (NEJM)
• Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system (ACP)
• Molnupiravir as early treatment for adults with COVID-19 (The Lancet)
• Higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support (medRxiv)
• FDA approves Tocilizumab for the treatment of COVID-19 in hospitalized adults (Roche)
• Structural brain changes in post-acute COVID-19 patients with olfactory dysfunction (Annals)
• Paxlovid patient eligbiliity screening checklist (FDA)
• Persistent post–COVID-19 smell loss association (Science)
• Epidemiology of long COVID in US adults (CID)
• Persistent symptoms & sequelae after SARS-CoV-2 infection not requiring hospitalization (OFID)
• Outpatient treatment of COVID-19 with metformin, ivermectin, and fluvoxamine & the development of long COVID (medRxiv)
• Contribute to our MicrobeTV fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 970
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]